The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Next-generation sequencing (NGS) has transformed advanced non-small cell lung cancer (NSCLC) treatment via targeted therapies for specific oncogenic driver alterations (e.g., EGFR, ALK, ROS1).
• While primarily used for systemic therapy in metastatic NSCLC to identify targets, resistance, and response, NGS has significant untapped potential in earlier disease stages.

Purpose of the Study:

• To review the emerging applications of NGS in non-small cell lung cancer patients undergoing curative-intent surgery.
• To explore how NGS can elucidate tumor biology, predict recurrence, and guide perioperative therapies in early-stage NSCLC.

Main Methods:

• Review of current literature on NGS applications in early-stage NSCLC.
• Discussion of specific NGS uses including tumor heterogeneity analysis, genomic correlation with adenocarcinoma subtypes, recurrence prediction, and circulating tumor DNA (ctDNA) applications.
• Examination of NGS for differentiating primary tumors from metastases and guiding neoadjuvant/adjuvant treatments.

Main Results:

• NGS is crucial for understanding tumor genomics in lung adenocarcinoma subtypes and assessing tumor heterogeneity.
• Plasma ctDNA detected via NGS shows promise for early cancer detection and minimal residual disease monitoring.
• NGS aids in distinguishing separate primary lung cancers from intrapulmonary metastases and informs adjuvant therapy decisions.

Conclusions:

• NGS offers significant potential beyond systemic therapy, providing critical insights for early-stage non-small cell lung cancer management.
• Applications include predicting recurrence post-surgery, guiding perioperative treatments, and improving diagnostic accuracy in complex cases.
• The integration of NGS into the surgical management of NSCLC is poised to enhance patient outcomes and personalize treatment strategies.